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1. Introduction 
1.1. What are lipids? 
Lipids consists of a broad group of naturally occurring molecules that include fats, waxes, 
sterols including cholesterol, fat-soluble vitamins (such as vitamins A, D, E, and K), 
monoglycerides, diglycerides, triglycerides, phospholipids, and others. Lipids were 
previously known as sources of energy storage and the building blocks for cell membrane. 
Lipids are now known to play several key roles in intracellular signalling, membrane 
trafficking, hormonal regulation, blood clotting (Muller-Roeber and Pical, 2002; Vance and 
Vance, 2002; Fahy et al., 2009). All lipids may be defined as hydrophobic or amphiphilic 
small molecules. The amphiphilic nature of some lipids allows them to form structures such 
as vesicles, liposomes, or membranes in an aqueous environment. Biological lipids originate 
entirely or in part from two distinct types of biochemical subunits, which are ketoacyl and 
isoprene groups (Fahy et al., 2009).  
Lipids typically do not travel alone in the blood. Instead, it binds to a protein that transports 
it to its destination in the body. The complex formed by the binding of lipid to protein i.e. 
lipoprotein, makes lipids water soluble, which enables its transportation in blood. The 
lipoprotein particle is composed of an outer shell of phospholipids, which renders the 
particle soluble in water; a core of fats called lipid, including cholesterol and a surface 
apoprotein (apolipoprotein). Ideally, the lipoprotein aggregates should be described in 
terms of the different protein components (apolipoprotein) because this determines the 
overall structures and metabolism of the lipoprotein, and the interactions with receptor 
molecules in liver and peripheral tissues. The apolipoprotein molecule enables tissues to 
recognize and take up the lipoprotein particle. However, lipoproteins are classified based on 
their characteristic density on ultracentrifugation, which has been used to segregate the 
different lipoprotein classes. Lipoproteins are broadly classified as high density lipoprotein 
(HDL), low density lipoprotein (LDL), intermediate density lipoprotein (IDL), very low 
density lipoprotein (VLDL) and chylomicrons (CM). Each of these particles perform 
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different functions and can be detrimental (VLDL, IDL, LDL) or beneficial (HDL) to the 
cardiovascular system. 
 
Figure 1. Structure of Lipoprotein available from http://www.campbell.edu 
 CM VLDL IDL HDL 
Density (g/ml) < 0.94 0.94 – 1.006 1.006 – 1.063 1.063 -1.210 
Diameter (Á) 6000 - 2000 600 250 70-120 
Total lipid (wt %) * 99 91 80 44 
Triacylglycerols 85 55 10 6 
Cholesterol esters 3 18 50 40 
Cholesterol 2 7 11 7 
Phospholipids 8 20 29 46 
*Most of the remaining materials comprise the various apolipoproteins 
Table 1. Physical properties and lipid compositions of lipoprotein classes 
1.2. Role of cholesterol in membrane dynamics 
It is relevant to establish the important of cholesterol in the body to be able to relate the 
various metabolic events associated with cholesterol and its homeostasis. Mammalian cell 
membranes contain varying proportions of cholesterol depending on organelle and cell 
type. These levels are tightly controlled by lipid transfer, through both vesicular and 
protein-bound pathways. With its rigid sterol backbone, cholesterol preferentially locates 
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among saturated membrane lipids that have straight, elongated hydrocarbon chains rather 
than among kinked, unsaturated species. The presence of cholesterol in the membrane 
increases lateral ordering of lipids, reducing permeability and fluidity and potentially 
restricting diffusion of membrane proteins. Its distribution is not uniform within a 
membrane: regions of high cholesterol and corresponding low fluidity are termed lipid rafts. 
These areas act as platforms for the assembly of signalling complexes within the membrane 
and have been implicated in the development of numerous disease processes, notably 
arteriosclerosis and cancer (Di Vizio et al., 2008; Ikonen, 2008). 
2. Cardiovascular disease and risk factors 
Elevated plasma levels of low density lipoprotein (LDL) and low levels of high density 
lipoprotein (HDL) poses a major risk of development of cardiovascular diseases (Grundy et 
al., 1999). A dietary intake of saturated fat and a sedentary lifestyle has been associated with 
about 31% of coronary heart disease and 11% of stroke in humans. According to the 
Framingham Heart Study and other studies (Wilson et al., 1998), the major and independent 
risk factors for coronary heart disease (CHD) are cigarette smoking of any amount, elevated 
blood pressure, elevated serum total cholesterol and low-density lipoprotein cholesterol 
(LDL-C), low serum high-density lipoprotein cholesterol (HDL-C), diabetes mellitus, and 
advancing age. More recently, a review by Patrick and Uzick (2001) documented new risk 
factors for CHD which included levels of circulating homocysteine, fibrinogen, C-reactive 
protein (CRP), endogenous tissue plasminogen-activator, plasminogen-activator inhibitor 
type I, lipoprotein(a), factor VII and certain infections such as Chlamydia pneumonia. These 
studies showed that the total risk of an individual is the summation of all major risk factors.  
Other factors contributing to the total risk for CHD are categorized as conditional risk 
factors and predisposing risk factors. The conditional risk factors are associated with 
increased risk for CHD, although their causative, independent, and quantitative 
contributions to CHD have not been well documented. The predisposing risk factors are 
those that worsen the independent risk factors. Two of these risk factors; obesity and 
physical inactivity, are designated major risk factors by the American Heart Association 
(AHA) (Fletcher et al., 1996; Eckel, 1997). The adverse effects of obesity are worsened when it 
is expressed as abdominal obesity, an indicator of insulin resistance. These risk factors apply 
before clinical manifestation of coronary atherosclerotic diseases. The clinical significance of 
these risk assessment is to identify high-risk patients who require attention, motivate 
patients to adhere to risk-reduction therapies and modify the intensity of risk reduction 
effort required in potential patients (Grundy et al., 1999). 
2.1. Lipoproteins, cholesterol and atherosclerosis 
Cholesterol is a building block of the outer layer of cell membranes. Cholesterol is a waxy 
steroid of fat that is produced in the liver or intestines. It is used to produce hormones and 
cell membranes and is transported in the blood plasma of all mammals (Leah, 2009). As an 
essential structural component of mammalian cell membranes, it is required to establish 
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proper membrane permeability and fluidity. In addition, cholesterol is an important 
component for the manufacture of bile acids, steroid hormones, and vitamin D. Cholesterol 
is the principal sterol synthesized by animals; however, small quantities can be synthesized 
in other eukaryotes such as plants and fungi. It is almost completely absent among 
prokaryotes including bacteria (Pearson et al., 2003). 
Owing to its limited solubility in water, cholesterol is transported in blood in lipoproteins. 
The lipoprotein outer layer is formed of amphiphilic cholesterol and phospholipid 
molecules, studded with proteins, surrounding a hydrophobic core of triglycerides and 
cholesterol esters. Lipoproteins are specifically targeted to cells by distinct apolipoproteins 
on their surface that bind to specific receptors. Low density lipoprotein (LDL) contains the 
highest level of cholesterol. LDL receptors in peripheral tissues bind LDL, triggering its 
endocytosis, lysosomal targeting and hydrolysis. When cells have abundant cholesterol, 
LDL receptor synthesis is inhibited by the sterol regulatory element binding proteins 
(SREBP) pathway (Wang et al., 1993; Yokoyama et al., 1993; Brown and Goldstein, 2009).  
The biosynthesis of cholesterol is intensely regulated in the body with negative feedback of 
plasma cholesterol levels. The molecular basis of this regulation was set out by Michael 
Brown and Joseph Goldstein, earning them the Nobel Prize in Physiology and Medicine in 
1985 (Leah, 2009). A key irreversible step of cholesterol synthesis is catalyzed by HMG-CoA 
reductase. Transcription of the HMG gene is controlled by SREBPs, transcription factors that 
bind sterol regulatory elements. SREBPs are only able to enter the nucleus when cholesterol 
levels fall. At other times they are tied up in a complex that includes Scap (SREBP-cleavage 
activating protein), an escort protein with a cholesterol-binding motif that senses cellular 
cholesterol levels. The SREBP pathway is now implicated in multiple regulatory aspects of 
lipid formation and metabolism (Brown and Goldstein, 2009). 
2.2. Atherogenicity of lipoprotein sub-fractions 
The first stages of cholesterol build up in the blood vessels (atherosclerosis) occur when LDL 
particles circulating in the blood penetrate through the inner lining of blood vessels and 
become trapped in the artery wall. The normal function of LDL is to deliver cholesterol to 
cells, where it is used in membranes or for the synthesis of steroid hormones. Cells take up 
cholesterol by receptor-mediated endocytosis. LDL binds to a specific LDL receptor and is 
internalized in an endocytic vesicle. Receptors are recycled to the cell surface, while 
hydrolysis in an endolysosome releases cholesterol for use in the cell. The liver removes 
LDL and other lipoproteins from the circulation by receptor-mediated endocytosis. 
Deregulation of cholesterol levels results in the existence of more LDL in the blood than can 
be taken up by LDL receptors. Excess LDL is oxidized and taken up by macrophages, 
forming foam cells that can become trapped in the walls of blood vessels along with cells of 
inflammation (Zioncheck et al., 1991; Young and McEneny, 2001). Fatty streaks, consisting of 
subendothelial collection of foam cells are initially formed in blood vessels. Small, dense 
LDL particles are more atherogenic than large, buoyant LDL particles, and oxidation of LDL 
also increases its atherogenicity. In addition, LDL belongs to the group of lipoproteins that 
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contain apolipoprotein (apo) B-100. Some of the particles in this highly heterogeneous group 
contain other apolipoproteins, such as apo C-II, apo C-III, and apo E. Furthermore, some 
particles are larger and rich in triglycerides (large VLDL), whereas others are smaller and 
rich in cholesteryl esters (small VLDL, IDL). It is now known that remnant lipoproteins 
containing apo C-III are highly atherogenic and may be more specific measures of coronary 
heart disease (CHD) risk assessment than plasma triglycerides (Carmena et al., 2004).  
The end result is the formation of an atherosclerotic plaque which occludes the endothelial 
lumen and impedes blood flow, leading to myocardial infarction, the major cause of heart 
attacks and strokes. Although LDL levels correlate with heart attack risk, high density 
lipoprotein (HDL) has an inverse ratio of risk because HDL particles transport cholesterol to 
the liver for excretion. Modern cholesterol tests distinguish the LDL/HDL ratio as well as the 
overall level (Barter et al., 2007). Other sub-fractions of lipoproteins such as chylomicrons, 
IDL and VLDL may enter the endothelial spaces due to their sizes, thus contribute 
substantially to development of atherosclerotic plaques. They may also increase 
prothrombotic factors, triggering cardiovascular diseases (Brunzell et al., 2008). 
 
Figure 2. Sizes of Lipoproteins available at http://www.sigmaaldrich.com/european-export.html 
Triglyceride-rich lipoproteins comprise a great variety of nascent and metabolically 
modified lipoprotein particles differing in size, density, and lipid and apolipoprotein 
composition. Studies have shown an inverse relationship between the size of lipoproteins 
and their ability to cross the endothelial barrier to enter the arterial intima. Chylomicrons 
and large VLDLs are probably not capable of entering the arterial wall. On the other hand, 
small VLDL and IDL can enter the arterial intima. Therefore, certain triglyceride rich 
lipoproteins are atherogenic, whereas others are not. A large body of evidence suggests that 
small VLDLs and IDLs are independently associated with atherosclerosis (Carmena et al., 
2004). 
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2.3. Apolipoproteins in lipoproteins 
Apolipoproteins are the carrier proteins for lipoproteins and they consist of a single 
polypeptide chain often with relatively little tertiary structure. They are required to 
solubilise the non-polar lipids in the circulation and in some instances to recognise specific 
receptors. They are classified as Apo A1, A2, A4, A5, B48, B100, C1, C2, C3, D, E, H, J, L, M 
and Apo (a). Most apolipoproteins are synthesised by the liver and intestine. 
Apolipoprotein Molecular weight Lipoprotein Function 
Apo AI 29,100 HDL Lecithin: cholesterol 
acyltransferase (LCAT) activation. 
Main structural protein. Binds 
ABCA1 on macrophages 
Apo AII 17,400 HDL Enhances hepatic lipase activity 
Apo AIII 46,000 CM
Apo AIV 46,000 HDL, CM Inhibits food intake in CNS 
Apo AV 39,000 HDL Enhances triacylglycerol uptake 
Apo B48 241,000 CM Derived from Apo B100 gene by 
RNA editing, lacks the LDL 
receptor binding site
Apo B100 512,000 LDL, IDL, VLDL Binds to LDL receptor 
Apo CI 7,600 VLDL, CM Activates LCAT
Apo CII 8,900 VLDL, CM Activates lipoprotein lipase 
Apo CIII 8,750 VLDL, CM Inhibits lipoprotein lipase 
Apo D 33,000 HDL Closely associated with LCAT, 
progesterone binding 
Apo E 34,000 HDL At least 3 forms. Binds to LDL 
receptor
Apo(a) 300,000 – 800,000 LDL, Lp(a) Linked by disulfide bonds to apo 
B100 and similar to plasminogen, 
associated with premature 
coronary artery disease and stroke 
Apo H 50,000 Chylomicrons Involved with triacylglycerol 
metabolism
Apo M HDL Transports sphingosine-1- 
phosphate
Table 2. Classes of apolipoproteins, their molecular weight and functions 
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2.3.1. Apolipoprotein A 
Apo A are subdivided into apo AI, AII, AIII, AIV and AV. Apo AI and AII are the major 
apolipoproteins in the HDL particle. HDL is primarily saddled with the responsibility of 
removing excess cholesterol from peripheral tissues and delivering it to the liver for 
excretion in bile as bile acids in a process known as reverse cholesterol transport. Apo AI is 
synthesised mainly by the liver and also by the intestine. The protein consists of 243 amino 
acids arranged as eight α-helical segments of 22 amino acids which have 11 –mer repeats, no 
disulfide bonds or glycosylations. The helices are believed to be amphipathic in nature with 
both hydrophobic and hydrophilic faces. This nature enhances its interaction with the lipid 
and aqueous phases. Apo AII on the other hand is found as a twin chain of 77 amino acids 
each, linked by disulfide bonds. It enhances the activity of hepatic lipase, thus increasing 
lipoprotein metabolism. Apo III is found in chylomicrons. 
2.3.2. Apolipoprotein E 
Three isoforms of this apolipoprotein exist and they are all synthesised mainly by the liver 
and also by several tissues such as arterial wall, brain and adipose tissue. They are 
important for homeostasis of lipid and lipoproteins in blood circulation as well as their 
metabolism in these tissues. Apo E is required for the clearance of VLDL remnant (IDL) 
from circulation in the liver. Other suggestions on its involvement with immune response 
and inflammation have also been put forward.  
2.3.3. Apolipoprotein B 
Two types of apolipoprotein B are synthesised from the intestine and liver as apo B100 
which has the full length of 4536 amino acid residues and a truncated form with 48% of the 
full length known as apo B48. These proteins which are synthesised on ribosomes, an 
organelle located on the surface of rough endoplasmic reticulum are translocated through 
the reticular membrane into the lumen of endoplasmic reticulum. Assembly of VLDL occurs 
here by accretion of lipids to the core of apo B particle. This occurs in three distinct stages as 
the apo B grows bigger, forming the pre-VLDL to VLDL 2 which eventually grows to 
become the triacylglycerol-rich VLDL 1 or chylomicrons, the most energy dense substances 
in the body. VLDL 2 is a triacylglycerol-poor version of VLDL and its assembly occurs in 
golgi bodies. This is transported to basolateral membrane of the intestinal cells where final 
assembly of VLDL 1 or chylomicrons occur and these are secreted into the lamina propria of 
the intestinal cells by reverse exocytosis.  
Apo B100 and B48 are large and water-insoluble, and are the only non-exchangeable 
apolipoproteins. They are major components of chylomicrons and VLDL, and usually 
remain with their lipid aggregates throughout their passage in plasma and several metabolic 
changes occurring during their circulation in plasma. Chylomicrons are usually transported 
through the intestinal lymphatic system and flow into blood circulation via the left 
subclavian vein. As apo B carries the VLDL or chylomicrons through the blood stream, their 
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triacylglycerol content are removed by peripheral tissues via enzymatic activity of 
lipoprotein lipase, located in the endothelial wall. This makes free fatty acids available for 
energy production in muscle and some are stored in adipose tissue. Apo B48 remains with 
the remnant of the lipoprotein particle, along with dietary cholesterol and apo E. the 
lipoprotein remnant is eventually cleared from circulation in the liver by an apo E 
dependent receptor-mediated reaction.  
ApoB-100 is one of the largest monomeric proteins known and it is the major apolipoprotein 
component common to the atherogenic lipoproteins [VLDL, LDL, IDL and Lp(a)] 
(Boerwinkle et al., 1992; Carmena et al., 2004). Apo B100 differs from apo B48 by the presence 
of LDL receptor site on the apo B100 molecule. Apo B-100 is encoded for by the Apo B gene 
and mutations in this gene cause familial hypercholesterolemia, an autosomal hereditary 
metabolic disorder. The level of apo B-100 is a stronger predictor of risk than LDL in 
humans. Apo B-100 is speculated to mediate delivery of the cholesterol content of 
lipoproteins to cells via an unknown mechanism. It is well established that Apo B-100 is 
associated with atherogenic lipoproteins, thus the number of Apo B-100 can be used to 
determine the risk of atherosclerosis and CHD in individuals. Apo B-100/apo A-I ratio are 
strongly and positively related to increased risk of fatal myocardial infarction. 
Apolipoprotein A-I (apo A-I) is the major apolipoprotein in the HDL structure. The Apo B-
100/apo A-I ratio is especially valuable in patients with normal or low LDL concentrations, a 
frequent observation in type 2 diabetes mellitus which may present with 
hypertriglyceridemia and hyper-apo B concentrations (Carmena et al., 2004).  
2.3.4. Apolipoprotein C 
Apolipoprotein C is subdivided into three and each has its own distinct function. Apo CI is 
involved with activation of Lecithin: cholesterol acyltransferase (LCAT) along with apo AI. 
This enzyme converts free cholesterol into cholesterol ester, which enhances the 
incorporation of cholesterol into the lipid core of a lipoprotein particle, particularly in 
assembly of HDL particle. The enzyme is mainly bound to HDL and LDL in plasma. Apo 
CII and CIII have antagonistic activity to each other which are required in regulation of 
lipoprotein lipase activity. Apo CII is required for activation of lipoprotein lipase, while CIII 
inhibits lipoprotein lipase activity. Apo CII is believed to open a lid-like region of the 
enzyme which allows the active site to hydrolyse the fatty acid ester bonds of 
triacylglycerols. In addition to inhibition of lipoprotein lipase, apo CIII also inhibits the 
binding of lipoproteins to receptors at the cell surface, thereby decreasing hydrolysis of 
triacylglycerols. High levels of apo CIII have been associated with elevated serum levels of 
triacylglycerols (hypertriglyceridemia).  
2.3.5. Transfer of apolipoproteins in lipoprotein homeostasis 
Lipids enter blood circulation bound to apolipoproteins as chylomicrons or VLDL which as 
secreted into the blood stream from the intestines. Chylomicrons or VLDL consist mainly of 
apo B100 and B48, but also consist of some apo AI, along with other apolipoprotein which 
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will be discussed. These lipoproteins carry triacylglycerol-rich cholesterols to the peripheral 
tissues to provide sources of energy and for storage, while HDL carries excess cholesterol 
from peripheral tissue to the liver for excretion in bile acids. Immediately chylomicrons 
enter blood circulation, an exchange of apolipoproteins occurs between chylomicrons and 
HDL. The apo AI content of chylomicrons is exchanged for the apo C and E content of HDL. 
Apo C content is required for activation and inhibition of lipoprotein lipase which 
hydrolyses the triacylglycerol content of chylomicrons and VLDL, while apo E is needed for 
the receptor mediated clearance from circulation. Circulation of VLDL and chylomicrons in 
the blood stream exposes the particles to enzymatic release of triacylglycerols from the 
lipoprotein core and excess cholesterol is removed from cells. The triacylglycerol- poor and 
cholesterol rich LDL remnant produced is potentially toxic to the body and needed to be 
safely cleared from blood circulation. The main concern for this lipoprotein is its toxic effect 
on the cardiovascular system. The liver scavenges and disposes chylomicrons remnant more 
effectively than the LDL particles, a mechanism put in place by the body to get rid of the 
more atherogenic particle of the two; chylomicrons remnant. LDL particles are mostly 
removed by other mechanisms involving HDL. 
2.3.6. Apolipoprotein(a) 
Apolipoprotein(a) itself is a large glycoprotein that exhibits size heterogeneity among 
individuals with isoforms that range between 180 – 700kDa in size. Apo(a) genotypes were 
determined using a newly developed pulsed-field gel electrophoresis method which 
distinguished 19 different genotypes at the apo(a) locus. The apo(a) gene itself was found to 
account for virtually all the genetic variability in plasma Lp(a) levels (Boerwinkle et al., 
1992). The apo(a) cDNA contains multiple tandem copies of a sequence that encodes a 
cysteine-rich protein motif called a kringle. The particular repeated kringle in apo(a) is 
designated kringle 4 because it closely resembles the fourth kringle in plasminogen, with the 
protease domain of apo(a) containing 88% amino-acid identity to plasminogen. McLean et al. 
(1992) proposed that the apo(a) isoforms are of different sizes because of variations in the 
numbers of kringle 4-encoding repeats in the apo(a) gene. The molecular mass of apo(a) 
protein varies from 187 kDa for an apo(a) that contains 12 kringle 4 domains, to 662 kDa for 
an apo(a) that contains 50 kringle 4 domains (Carmena et al., 2004). 
2.4. Lipoprotein A [Lp(a)] 
Lipoprotein [Lp(a)] is a variant of LDL with an additional apolipoprotein in the structure. 
Lp(a) is essentially an LDL particle with a large glycoprotein, apolipoprotein (a) [apo(a)] 
attached to it (McLean et al., 1987; Loscalzo et al., 1990; Boerwinkle et al., 1992; Palabrica et al., 
1995). Lp(a) resembles low density lipoprotein (LDL) in lipid composition, but it is 
distinguished by the presence of apo(a) which is bound by a disulfide linkage to 
apolipoprotein B-100, a ligand in the LDL molecule by which LDL binds to its receptor. 
Lp(a) levels has been demonstrated to have a clear association with development of 
atherosclerosis and other cardiovascular diseases (Zenker et al., 1986; Danesh et al., 2000; 
Berglund and Anuurad, 2008; Danik et al., 2008). The postulated atherogenicity of Lp(a) is 
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probably due to the presence of apo(a) component of the Lp(a) molecule. A study showed 
that the removal of apo(a) from Lp(a) particles result in a lipoprotein with greatly enhanced 
affinity for the LDL receptor (Armstrong et al., 1985). 
2.4.1. Synthesis of lipoprotein(a)  
Apo(a) is expressed by liver cells (hepatocytes), and the assembly of apo(a) and LDL 
particles seems to take place at the outer hepatocyte surface. The half-life of Lp(a) in the 
circulation is about 3 to 4 days (Rader et al., 1993) and this particle varies in blood 
concentration from one individual to another from <0.2 - >200 mg/dL. Ethnicity is a factor, 
with those of Asian and African origin averaging the highest concentrations. Within ethnic 
groups, individual elevation of Lp(a) is directly associated with increased risk of 
cardiovascular diseases (Sandholzer et al., 1991; Chien et al., 2008). Lp(a) is usually 
unaffected by factors like age, blood pressure, and total cholesterol.  
2.4.2. Similarity between lipoprotein(a) and plasminogen 
The structure of Lp(a) is similar to plasminogen, a naturally occurring glycoprotein that 
participates in dissolving of clots that form in the bloodstream, and tissue plasminogen 
activator (tPA). Lp(a) competes with plasminogen for its binding site, leading to reduced 
fibrinolysis (Loscalzo et al., 1990; Palabrica et al., 1995). Also because Lp(a) stimulates 
secretion of PAI-1 it leads to thrombogenesis. In addition, because of LDL cholesterol 
content, Lp(a) contributes to atherosclerosis (Schreiner et al., 1993; Sotiriou et al., 2006) and 
ultimately a cardiovascular risk factor (Berglund and Ramakrishnan, 2004).  
2.4.3. Correlation between apolipoprotein size and Lp(a) concentration 
There is a general inverse correlation between the size of the apo(a) isoform and the Lp(a) 
plasma concentration (Bowden et al., 1994; Kraft et al., 1996) which is caused by a variable rate 
of degradation before the apo(a) protein has matured for Lp(a) assembly (White et al., 1994). 
The plasma concentration of Lp(a) is unaffected by many physiological, pharmacological, and 
environmental factors that affect the levels of other plasma lipoproteins (Albers et al., 1977). A 
genetic determination of plasma Lp(a) levels was strongly suggested due to this lack of 
environmental and physiological influences. Consistent with this formulation, early genetic 
studies suggested that the presence of Lp(a) in plasma was inherited as a single autosomal 
dominant trait (Berg and Mohr, 1963; Iselius et al., 1981), with an estimated heritability level 
ranging from 0.75 to 0.98 (Boerwinkle et al., 1992).  
Plasma Lp(a) concentrations vary 1000-fold between individuals and represent a continuous 
quantitative genetic trait with a skewed distribution in Caucasian populations (Utermann, 
1989). A study was conducted by Lackner et al. (1991) in which the apo(a) gene of members 
of 12 Caucasian families were segregated. It was found that within a given family, sibling 
pairs with identical apo(a) genotypes tended to have very similar plasma Lp(a) levels 
(Lackner et al., 1991). However, individuals with the same apo(a) genotypes who were 
members of different families often had significantly different plasma concentrations of 
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Lp(a). Taken together, these observations suggest that the apo(a) gene is the major 
determinant of plasma Lp(a) levels and that cis-acting DNA sequences at or near the apo(a) 
locus, other than the number of kringle 4 repeats, contribute importantly to plasma Lp(a) 
concentrations (Boerwinkle et al., 1992). Variation in the hypervariable apo(a) gene on 
chromosome 6q2.6-q2.7 and interaction of apo(a) alleles with defective LDL-receptor genes 
explain a large fraction of the variability of plasma Lp(a) concentrations (Utermann, 1989). 
Furthermore, the size of the apo(a) glycoprotein varies in individuals and this size is 
inversely correlated with the plasma level of Lp(a). The reason for the inverse correlation 
between the size of the apo(a) gene and level of plasma Lp(a) is not known, but a variation 
of length within the kringle 4-encoding region of the apo(a) gene may account for a greater 
proportion of the inter-individual variation in plasma Lp(a) concentrations. Also, the 
number of kringle 4 repeats in the gene may not have a direct effect on plasma Lp(a) 
concentration (Boerwinkle et al., 1992; Brunner et al., 1996). A study conducted on apo(a) 
gene of mamorset monkeys showed a plasma Lp(a) concentration of a very wide range of 
over a 100-fold, but only one apo(a) isoform (Guo et al., 1991). This may be explained by the 
differences in the composition of kringle 4 sequence of apo(a) genes in which individuals 
may have same sizes of apo(a) alleles but different plasma Lp(a) concentrations. The 
frequency of recombination activity in this locus may be responsible for the variation in 
their kringle 4 composition and number which may have marked effect on synthesis and /or 
degradation of Lp(a) (Boerwinkle et al., 1992). 
2.5. Role of oxidation in atherogenesis 
Oxidative stress, especially LDL oxidation has been suggested for almost three decades as 
the most probable aetiology of atherosclerosis (Steinbrecher et al., 1984). Markers of LDL 
oxidation in plasma, particularly circulating oxidized LDL and auto-antibodies against 
oxidized LDL, could be used to assess the development of atherosclerosis in patients 
(Carmena et al., 2004). Circulating oxidized LDL is additive to the global risk score based on 
age, sex, total and HDL cholesterol, diabetes mellitus, hypertension, and smoking as a useful 
marker for identifying persons at risk for CAD (Holvoet et al., 2001; Toshima et al., 2000). 
A study has associated circulating oxidized LDL with both subclinical atherosclerosis 
(clinically silent ultrasound assessed atherosclerotic changes in the carotid and femoral 
arteries) and inflammatory variables (C-reactive protein and the inflammatory cytokines 
interleukin-6 and tumor necrosis factor-α). This conclusion supports the concept that 
oxidatively modified LDL may play a major role in development of atherosclerosis (Hulthe 
and Fagerberg, 2002). It has been proposed that, because of the antigenic properties of 
oxidized LDL, the anti-oxidized LDL antibody titer could represent a useful index of in vivo 
LDL oxidation. Autoantibodies against oxidized LDL have been reported to be associated 
with atherosclerosis, but existing reports are still conflicting. Some studies have reported a 
positive relationship between autoantibodies against oxidized LDL and CHD (Sherer et al., 
2001) whereas another did not (Leinonen et al., 1998). There is a strong cross-reactivity 
between autoantibodies against oxidized LDL and anticardiolipin antibodies, which have 
been positively associated with CHD (Erkkila et al., 2000).  
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2.6. Relationship between insulin resistance, diabetes, and small, dense LDL  
Cardiovascular heart disease risk is usually significantly increased when elevated levels of 
small, dense LDL accompanied by hypertriglyceridemia, reduced HDL-cholesterol levels, 
abdominal obesity, and insulin resistance. Results from the Que´bec Cardiovascular Study 
have indicated that persons displaying elevated plasma concentrations of insulin and apo B 
together with small, dense LDL particles showed a remarkable increase in CHD risk 
(Lamarche et al., 1999).  
Sensitivity to insulin in diabetic and non-diabetic individuals was assessed using nuclear 
magnetic resonance (NMR) spectroscopy. Insulin resistance had profound effects on 
lipoprotein size and an increase in serum triglycerides. The lipid profile revealed a 2- to 3-
fold increase in concentrations of large VLDL particles with no change in medium or small 
VLDL, increase in overall LDL particle concentration with more small LDL particle size and 
reduced large LDL. In type 2 diabetes, these alterations could be attributed primarily to the 
underlying insulin resistance. These changes in the NMR lipoprotein subclass profile 
predictably increased the risk of cardiovascular disease but were not fully apparent in the 
conventional lipid profile (Garvey et al., 2003). The Diabetes Atherosclerosis Intervention 
Study (DAIS) (Vakkilainen et al., 2003) showed that lipid-modifying treatment decreased the 
angiographic progression of coronary atherosclerosis in subjects with type 2 diabetes. This 
effect was related in part to the correction of lipoprotein abnormalities. Compared with 
placebo, fenofibrate treatment significantly increased LDL particle size and HDL cholesterol 
and decreased plasma total cholesterol, LDL cholesterol, and triglyceride concentrations. 
The final LDL particle size was inversely correlated with the increase in percentage diameter 
stenosis (Vakkilainen et al., 2003). 
The Pittsburgh Epidemiology of Diabetes Complications Study on whether NMR 
lipoprotein spectroscopy improves the prediction of coronary artery disease (CAD) in 
patients with childhood-onset type 1 diabetes, independently of conventional lipid and 
other risk factors showed that both lipid mass and particle concentrations (NMR 
spectroscopy) of all VLDL subclasses, small LDL, medium LDL, and medium HDL were 
increased in CAD cases compared with controls, whereas large HDL was decreased. Mean 
LDL and HDL particle sizes were also less in CAD cases (Soedamah-Muthu et al., 2003; 
Carmena et al., 2004). 
2.7. Dyslipoproteinaemia 
Dyslipoproteinaemia is a term broadly used for derangement in lipid and lipoprotein 
metabolism, which may either be hyperlipoproteinaemia or hypolipoproteinaemia. 
Dyslipoproteinaemias are generally classified as familial (primary) or acquired (secondary). 
This chapter discusses hyperlipoproteinaemia with its close relevance to development of 
cardiovascular diseases. Primary hyperlipoproteinaemias are of genetic origin and may be 
due to a mutation in a receptor protein which presents as inborn errors of lipid metabolism, 
and includes common hypercholesterolemia, combined familiar hyperlipidemia, familiar 
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hypercholesterolemia, familiar hypertriglyceridemia, VLDL remnants hyperlipidemia and 
primary chylomicronaemia (Garmendia, 2003). Primary hyperlipoproteinaemia was first 
classified by Fredrickson and Lees (1965) and this classification was adopted by World 
Health Organization (WHO). They divided primary hyperlipoproteinaemias into four types 
and details are show in Table 3 below.  
The secondary hyperlipoproteinemias also mimic primary types and may present with 
similar symptoms. Secondary dyslipoproteinaemias are usually due to other underlying 
causes that lead to alterations in plasma lipid and lipoprotein metabolism, including 
hypothyroidism, diabetes mellitus, nephrotic syndrome, chronic biliary obstruction, renal 
insufficiency. Some drugs modify lipid metabolism and these include alcohol, beta-
adrenergic blockers, diuretics, progestagens, corticosteroids (Garmendia, 2003). Treatment 
of the underlying cause or discontinuation of offending drug may resolve the 
dyslipoproteinaemia. Lipid and lipoprotein abnormalities are common observations and are 
regarded as modifiable risk factors for development of cardiovascular diseases. 
Hyperlipo-
proteinaemia 
Sub-type Classification  Defect Lipoprotein 
increased 
Treatment 
 
Type I 
a, c  Familial 
hyperchylo-
micronemia  
↓ Lipoprotein 
lipase (LpL) 
 
Chylomicron
s 
 
Diet 
control 
b apoprotein CII 
deficiency 
Altered Apo 
CII 
 
Type II 
a Familial 
hypercholesterolem
ia 
LDL receptor 
deficiency 
LDL Bile acid 
sequestrant
s, 
statins,niac
in 
b Familial combined 
hyperlipidemia 
↓ LDL 
receptor or 
and ↑Apo B 
LDL and 
VLDL 
Statins, 
niacin,fibra
te 
Type III Familial 
dysbetalipo-
proteinaemia 
Apo E2 
synthesis 
IDL Fibrate, 
statins 
Type IV Familial 
hypertriglyce-
ridaemia 
↑VLDL and 
↓LpL 
VLDL Fibrate, 
niacin, 
statin 
Type V  ↑VLDL and 
↓LpL  
VLDL and 
chylomicrons 
Niacin, 
fibrate 
Adapted from Fredrickson classification of hyperdyslipoproteinaemia (Fredrickson and Lees, 1965). 
Table 3.  
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2.8. Theories of atherogenesis 
Arteries are blood vessels that carry oxygenated blood from the heart to all tissues of the 
body. The arterial wall is composed of three layers, namely the intima (inner lining), media 
and adventitia. A single layer of endothelial cells line the inner surface of the intima, 
forming a barrier to blood cells and plasma flowing within the blood vessel. Atherosclerosis 
is characterized by lesions in the intima of arteries, seen as raised fibrous plagues ranging in 
colour from pearly gray to yellowish gray. The cellular components of the plaque include a 
cell similar to the adjacent endothelial cell, macrophages, fibrinogen from which fibrin is 
formed and white blood cells intersparsed between dense connective tissue which consist 
majorly of collagen fibers. The cells within and around the plaque are usually lipid ladened. 
Atherosclerosis poses a high risk not just because it can close up an artery, slowing down or 
entirely restricting blood flow, but may also lead to thrombus formation. A thrombus is a 
complex aggregation of platelets, red and white blood cells in a fibrin network. Several 
theories have emanated, suggesting the actual pathogenesis of atherosclerosis. 
Schoenhagen (2006) documented the different theories that have been postulated in the 
course of history. In 1851, a scientist, Rokitansky suggested the encrustation theory or 
thrombogenesis in which it is said that atherosclerosis began in the intima of arteries with 
the deposition of thrombus. This is followed by the organisation of the thrombus through 
infiltration of fibroblast, secondarily followed by deposition of lipid. The German 
pathologist, Rudolf Virchow postulated the insudation or inflammation theory in 1856, a 
different initiation of atherosclerosis. It was suggested that infiltration of fatty substances 
from the blood stream into the arterial wall leads to deposition of cholesterol which acts as 
an irritant, causing inflammation and the proliferation of cells. The cholesterol deposits act 
as irritant in the arterial intima, initiating inflammatory process as macrophages are 
incriminated as key role players in the phases of the disease. This theory was further 
supported by the work of N.N. Anitschkow in 1933 where he discovered that a disease 
resembling human atherosclerosis could be reproduced in rabbits with high serum 
cholesterol or LDL levels. He thus stated this occurrence may be as a result of defects in 
metabolism of lipids and lipids Schoenhagen, 2006).  
The flow theory relates the circulation of blood in vessels to its effect on arterial wall. It 
stated that lesions occurred more often at curved, branching, or bifurcated sites, generally at 
regions of perturbed blood flow. Other hypotheses that arose from the flow theory include 
the stagnation point hypothesis by Fox and Hugh (1966), high wall shear stress hypothesis 
proposed by Fry (1968), low wall shear stress hypothesis by Caro et al. (1969), diminished 
lateral pressure hypothesis by Texon (1980) and the convection-diffusion hypothesis. 
All the theories above were established based on three methods. Atherosclerotic plaques 
from autopsy findings from individuals of both sexes, various ages and race with different 
diseases which included hyperlipidaemia, diabetes and hypertension were considered. 
Epidemiological studies of factors which promote or prevent development of 
atherosclerosis, and finally experimental pathology which established the sequence of lesion 
development or regression were considered. None of these theories entirely explains the 
pathogenesis of atherosclerosis, but each has explained an aspect of this process. 
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2.9. Prevention and treatment of cardiovascular diseases 
The contributing factors to development of cardiovascular diseases are numerous as 
mentioned in the risk factors above. Lowering of plasma cholesterol levels is usually the first 
line of intervention for prevention and treatment of cardiovascular diseases. Dramatic 
successes have been recorded with cholesterol-lowering therapy which may suggest that 
maintenance of low cholesterol levels is sufficient to prevent development of atherosclerosis 
or reversing an established disease condition (Brunzell et al., 2008). Different approaches 
have been used for prevention and treatment of this condition, some are enumerated below. 
2.9.1. Role of High density lipoprotein-cholesterol (HDL-C) 
High density lipoprotein-cholesterol (HDL-C) is the smallest of the lipoprotein sub-
fractions. It is however, the most complicated and diverse of the lipoproteins. It is the major 
lipoprotein which transports excess cholesterol from the plasma to the liver for excretion or 
utilization in the liver and other hormone producing regions of the body. Excess cholesterol 
is eliminated from the body via the liver, which secretes cholesterol in bile or converts it to 
bile salts (Toth, 2005; Tall, 2008). Also, its anti-inflammatory property protects LDL from 
oxidation and limits the concentrations of oxidized components, which may pose as 
atherogenic treats. HDL-C have been associated with reduced risk of cardiovascular events 
(Duffy and Rader, 2009; Khera et al., 2011). HDL-C plays a key role in the reverse 
transportation of cholesterol by accepting cholesterol from lipid-laden macrophages (Lehrke 
et al., 2007). In the study conducted by Khera et al. (2011), the ability of HDL to promote 
cholesterol efflux from macrophages was strongly and inversely associated with both 
subclinical atherosclerosis and obstructive coronary artery disease. It was also discovered 
that the associations persisted after adjustment for traditional cardiovascular risk factors, 
including the levels of HDL cholesterol and apolipoprotein A-I. HDL has several protein 
constituents which are exchangeable with other lipoproteins, and it acquires different 
apolipoproteins in the process of maturation such as apo AII, AIV, AV, CI, CII, CIII and E 
which results in generation of diverse HDL particles with various metabolic functions. In 
addition to being carrier proteins for the HDL particle, these proteins have protective roles 
which they play against cardiovascular diseases, such as by acting as anti-inflammatory 
regulators to limit the activity of pro-inflammatory cytokines. 
Nascent HDL is synthesised and secreted by the liver and small intestine. It travels in the 
circulation where it gathers cholesterol to form mature HDL, which then returns the 
cholesterol to the liver via various pathways. Apolipoprotein A-I (ApoA-I) is the major 
protein component of high density lipoprotein (HDL) in plasma. The protein is encoded for 
by APOAI gene (Breslow et al., 1982, Arinami et al., 1990). Defects in this gene have been 
associated with HDL deficiencies (HUGO Gene Nomenclature Committee, 2011). This 
protein increases the efflux of cholesterol from tissue to liver where it is excreted. A few 
individuals were reported to produce a HDL ApoA-I protein variant called ApoA-I Milano, 
an abnormal and apparently more efficient apolipoprotein. It has low measured HDL-C 
levels yet very low rates of cardiovascular events even with high blood cholesterol values 
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(Franceschini et al., 1981). Apo CI, CII and apo E also accumulate in the nascent HDL 
particle, which serves as a store for these apolipoproteins in circulation.  
Phospholipids are transferred from macrophages by a specific transporter molecule known 
as ATP-binding cassette transport protein A1 (ABCA-1) into the core of the lipoprotein, and 
cholesterols are extracted from the cells by a transporter protein derived from macrophages 
in the sub-endothelial spaces of tissues; ABCG-1 transporter. The eventual maturation of the 
HDL particle is dependent on the lecithin: cholesterol acyltransferase (LCAT), an enzyme 
activated by apoAI, which catalyses the formation of cholesterol esters from cholesterol. 
Mobilization of free cholesterol and phospholipids from IDL and LDL continues until a 
matured, spherical HDL particle is formed. Endocytosis of the matured HDL into 
hepatocytes occurs and the cholesterol and cholesterol esters are transported via a facilitated 
transfer to distinct pools within the cell. The modified HDL particles are secreted back into 
circulation where they can further acquire cholesterol before they re-circulate to the liver. 
The complete reverse cholesterol transport occurs with the addition of apo E to the HDL 
particle which facilitates their uptake and catabolism.  
2.9.2. Lipoprotein Lipase as an anti-atherogenic agent 
Activation of lipoprotein lipase (LpL) activity has been reported to have anti-atherogenic 
activity. Lipoprotein lipase (LpL) is a rate-limiting enzyme found on the surface of 
endothelial cells. It is polypeptide with 839 amino acids and an extracellular domain which 
binds to apo B100 and apo E. LpL catalyses the hydrolysis of the triacylglycerol (TAG) 
component of circulating chylomicrons and very low density lipoproteins (VLDL). The 
enzyme digests the TAG to fatty acids and monoglycerides. This provides non-esterified 
fatty acids and 2-monoacylglycerol which can be utilised immediately by cells for energy 
production or synthesis of other lipids. Unutilized fatty acids may be bound to circulating 
albumin and released slowly to meet future cellular requirements. Glycerol produced from 
LpL activity is transported back to the liver and kidneys, where it is converted to 
dihydroxyacetone phosphate in the alternative glycolytic pathway. The fatty acids from LpL 
activity in the muscle may diffuse into cells to be oxidized to two-carbon units or used to re-
synthesis TAG which are stored in adipose cells (Clee et al., 2000; Tsutsumi, 2003). 
Significant LpL activity occurs in muscle, adipose tissue and lactating mammary glands. 
Accumulation of VLDL remnants (IDL with apo B100 and apo E are converted to LDL with 
further loss of triacylglycerols. Both carrier proteins are necessary for recognition of IDL and 
LDL by the LDL receptors in the liver, after which they are taken up into hepatocytes by 
endocytosis and catabolized.  
Research carried out over the past two decades have not only established a central role for 
LpL in the overall lipid metabolism and transport but have also identified additional, non-
catalytic functions of the enzyme. Furthermore, abnormalities in LpL function have been 
found to be associated with a number of pathophysiological conditions, including 
atherosclerosis, chylomicronaemia, obesity, Alzheimer's disease, and dyslipidaemia 
associated with diabetes, insulin resistance, and infection (Mead et al., 2002).  
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Figure 3. Summary of the fate of Lipoprotein sub-fractions (Adapted from 
http://courses.washington.edu/conj/bess/cholesterol/liver.html) 
LpL encodes lipoprotein lipase, which is expressed in heart, muscle, and adipose tissue. LpL 
functions as a homodimer, and has the dual functions of triglyceride hydrolysis and 
ligand/bridging factor for receptor-mediated lipoprotein uptake. Through catalysis, VLDL is 
converted to IDL and then to LDL. Severe mutations that cause LpL deficiency result in type 
I hyperlipoproteinemia, while less extreme mutations in LpL are linked to many disorders 
of lipoprotein metabolism.  
LpL isozymes are regulated differently depending on the tissue. For example, insulin is 
known to activate LpL in adipocytes and its placement in the capillary endothelium. By 
contrast, insulin has been shown to decrease expression of muscle LpL (Kiens et al., 1989). 
The form that is in adipocytes is activated by insulin, whereas that in muscle and 
myocardium is activated by glucagon and epinepherine. This helps to explain why during 
fasting, LpL activity increases in muscle tissue and decreases in adipose tissue. After 
feasting, the opposite occurs (Braun and Severson, 1992; Mead et al., 2002).  
The concentration of LpL displayed on endothelial cell surface cannot be regulated by 
endothelial cells, as they neither synthesize nor degrade LpL. Instead, this regulation occurs 
by managing the flux of LpL arriving at the lipolytic site and being released into circulation 
attached to lipoproteins (Braun and Severson, 1992; Goldberg, 1996). The typical 
concentration of LpL in plasma is in the nanomolar range. Lipoprotein lipase deficiency 
leads to hypertriglyceridemia (elevated levels of triglycerides in the bloodstream) and 
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decreased high density lipoprotein activity (Clee et al., 2000; Tsutsumi, 2003; Okubo et al., 
2007). Diets high in refined carbohydrates have been shown to cause tissue-specific 
overexpression of LpL. This has been implicated in tissue-specific insulin resistance and 
consequent development of type 2 diabetes mellitus & obesity. 
2.9.3. Influence of Hormones on plasma LDL-C and Lp(a) levels 
Several studies have reported conflicting reports on the effect of hormonal replacement 
therapy on plasma LDL-C and Lp(a) levels (Taskinen et al., 1996; Shlipak et al., 2000; Vigna et 
al., 2002). In a cohort study conducted by Danik et al. (2008), the effect of hormone 
replacement therapy (HT) on Lp(a) and cardiovascular risk was investigated. It was 
reported that the relationship of high Lp(a) levels with increased cardiovascular disease is 
modified by hormonal therapy. These data suggest that the predictive utility of Lp(a) is 
markedly attenuated among women taking HT and may inform clinicians' interpretation of 
Lp(a) values in such patients. It was noteworthy that the effect of hormonal therapy was 
observed only in women with high LDL cholesterol levels, in agreement with previous 
studies suggesting an interaction between Lp(a) and LDL cholesterol (Berglung and 
Anuurad, 2008). 
3. Summary 
Elevated serum LDL-C and low levels of HDL-C are known as major and independent risk 
factors for CHD. Small, dense lipoprotein sub-fractions have been reported to have 
atherogenic potentials, with particular reference to Lipoprotein(a) [Lp(a)], a variant of low 
density lipoprotein (LDL). Other atherogenic sub-fractions of lipoproteins are VLDL, LDL, 
and IDL. These sub-fractions are characterized by the presence of apolipoprotein B-100, with 
an additional apolipoprotein known as apo(a) in the Lp(a) structure. Apo(a) is structurally 
and functionally similar to plasminogen and it accounts for virtually all the genetic 
variability in plasma Lp(a) levels. Variation of length within the kringle 4-encoding region 
of the apo(a) gene may account for a greater proportion of the inter-individual variation in 
plasma Lp(a) concentrations, with a strong genetic involvement inherited as a single 
autosomal dominant trait. 
In the course of the pathogenesis of atherosclerosis, oxidized LDL is taken up by 
macrophages and into endothelial cells. This leads to formation of atherosclerotic plaques 
which precedes development of CHD. Oxidized LDL is antigenic and titres of auto-
antibodies against oxidized LDL in plasma can be used as indicator of a positive association 
with CHD. A positive association has also been established between plasma level of LDL, 
specifically oxidized LDL and other risk factors contributing to development of CHD. Such 
risk factors were identified as hypertriglyceridemia, reduced HDL-C levels, abdominal 
obesity and insulin resistance. Treatment of CHD can be achieved by lowering of plasma 
cholesterol levels which has been achieved by cholesterol-lowering therapy, suggesting that 
maintenance of low cholesterol levels may sufficiently prevent or reverse an established 
atherosclerosis. Increasing plasma levels of HDL-C has been reported to also be of benefit. 
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HDL-C has anti-inflammatory activity which may prevent oxidation of LDL and it plays a 
key role in reverse transportation of cholesterol from lipid-laden macrophages. 
The enzyme Lipoprotein lipase (LpL) may be useful in chemotherapy or prophylaxis of 
CHD. LpL has anti-atherogenic activity by its dual functions of triglyceride hydrolysis and 
ligand/brigding factor for receptor-mediated lipoprotein uptake. Activation of the enzyme is 
dependent on the tissue, resulting in variability of its activity. Hormonal replacement 
therapy may also be of benefit to patients with CHD and related diseases, but reported on 
current findings are conflicting.  
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